99 related articles for article (PubMed ID: 10887044)
21. Neo-adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial.
Hartgrink HH; van de Velde CJ; Putter H; Songun I; Tesselaar ME; Kranenbarg EK; de Vries JE; Wils JA; van der Bijl J; van Krieken JH;
Eur J Surg Oncol; 2004 Aug; 30(6):643-9. PubMed ID: 15256239
[TBL] [Abstract][Full Text] [Related]
22. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil.
Hsu CH; Cheng AL; Hsu C; Yang CH; Lu YS; Lin CC; Bu CF; Yeh KH
Anticancer Res; 2002; 22(6B):3621-7. PubMed ID: 12552966
[TBL] [Abstract][Full Text] [Related]
23. Long-term results with FAMTX (5-fluorouracil, adriamycin, methotrexate) in advanced gastric cancer.
Klein HO
Anticancer Res; 1989; 9(4):1025-6. PubMed ID: 2817784
[TBL] [Abstract][Full Text] [Related]
24. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group.
Wils JA; Klein HO; Wagener DJ; Bleiberg H; Reis H; Korsten F; Conroy T; Fickers M; Leyvraz S; Buyse M
J Clin Oncol; 1991 May; 9(5):827-31. PubMed ID: 2016625
[TBL] [Abstract][Full Text] [Related]
25. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
26. Feasibility of a dose-intensive CMF regimen with granulocyte colony-stimulating factor as adjuvant therapy in premenopausal patients with node-positive breast cancer.
Bos AM; de Graaf H; de Vries EG; Piersma H; Willemse PH
Br J Cancer; 2000 Jun; 82(12):1920-4. PubMed ID: 10864198
[TBL] [Abstract][Full Text] [Related]
27. Cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) is more active than 5-fluorouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinoma.
Cocconi G; Carlini P; Gamboni A; Gasperoni S; Rodinò C; Zironi S; Bisagni G; Porrozzi S; Cognetti F; Di Costanzo F; Canaletti R; Ruggeri EM; Camisa R; Pucci F;
Ann Oncol; 2003 Aug; 14(8):1258-63. PubMed ID: 12881389
[TBL] [Abstract][Full Text] [Related]
28. Phase I studies of fluorouracil, doxorubicin and vinorelbine without (FAN) and with (SUPERFAN) folinic acid in patients with advanced breast cancer.
Goss PE; Fine S; Gelmon K; Rudinskas L; Ottaway J; Myles J; James K; Paul K; Rodgers A; Pritchard KI
Cancer Chemother Pharmacol; 1997; 41(1):53-60. PubMed ID: 9443614
[TBL] [Abstract][Full Text] [Related]
29. Biochemical modulation in the treatment of advanced cancer: a study of combined leucovorin, fluorouracil, and iododeoxyuridine.
Marshall JL; Richmond E; DeLap RJ
Clin Cancer Res; 1996 Sep; 2(9):1475-80. PubMed ID: 9816323
[TBL] [Abstract][Full Text] [Related]
30. Phase I study of docetaxel, oxaliplatin and capecitabine (TEX) as first line therapy to patients with advanced gastro-oesophageal cancer.
Andersen M; Schønnemann KR; Yilmaz M; Jensen HA; Vestermark LW; Pfeiffer P
Acta Oncol; 2010 Nov; 49(8):1246-52. PubMed ID: 20429725
[TBL] [Abstract][Full Text] [Related]
31. A phase II study of doxorubicin/paclitaxel plus G-CSF for metastatic breast cancer.
Schwartsmann G; Mans DR; Menke CH; Xavier N; Caleffi M; Ferreira Filho AF; Schunemann H; Kalakun L; Koya R; Pohlman P; Venegas LF
Oncology (Williston Park); 1997 Apr; 11(4 Suppl 3):24-9. PubMed ID: 9144687
[TBL] [Abstract][Full Text] [Related]
32. Phase II study of sequential high-dose methotrexate (MTX) and 5-fluorouracil (F) alternated with epirubicin (E) and cisplatin (P) [FEMTX-P] in advanced gastric cancer.
Roelofs EJ; Wagener DJ; Conroy T; Wils J; Burghouts JT; Fickers M; de Graeff A; Lalisang F; Paillot B
Ann Oncol; 1993 May; 4(5):426-8. PubMed ID: 8353077
[TBL] [Abstract][Full Text] [Related]
33. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial.
Waters JS; Norman A; Cunningham D; Scarffe JH; Webb A; Harper P; Joffe JK; Mackean M; Mansi J; Leahy M; Hill A; Oates J; Rao S; Nicolson M; Hickish T
Br J Cancer; 1999 Apr; 80(1-2):269-72. PubMed ID: 10390007
[TBL] [Abstract][Full Text] [Related]
34. Shorter interval between cycles of cyclophosphamide, doxorubicin, cisplatin using recombinant human granulocyte colony-stimulating factor for urothelial cancer--phase I/II study.
Yoshida O; Kakehi Y; Arai Y; Tomoyoshi T; Okada Y; Matsuda T; Mikami O; Fukuyama T; Hida S; Okabe T
Int J Urol; 1995 Nov; 2(5):316-21. PubMed ID: 8749950
[TBL] [Abstract][Full Text] [Related]
35. Growth factor allows effective dose-intensive regimen in advanced breast cancer patients.
Oncology (Williston Park); 1995 Jul; 9(7):684. PubMed ID: 8924381
[No Abstract] [Full Text] [Related]
36. [Chemotherapy with low-dose CDDP and continuous 5-FU for the treatment of advanced gastric cancers].
Tsuji A; Morita S; Horimi T; Takasaki M; Takahashi I; Shirasaka T
Gan To Kagaku Ryoho; 1999 Jun; 26(7):933-8. PubMed ID: 10396320
[TBL] [Abstract][Full Text] [Related]
37. A new schedule for etoposide, epidoxorubicin and cisplatin with granulocyte colony stimulating factor for advanced gastric cancer: a feasibility study.
Pronzato P; Vigani A; Pensa F; Botto F; Ghio E; Neri E; Tognoni A; Vaira F
Anticancer Res; 1997; 17(5B):3873-6. PubMed ID: 9427795
[TBL] [Abstract][Full Text] [Related]
38. Phase I evaluation of continuous 5-fluorouracil infusion followed by weekly paclitaxel in patients with advanced or recurrent gastric cancer.
Kondo K; Kobayashi M; Kojima H; Hirabayashi N; Kataoka M; Araki K; Matsui T; Takiyama W; Miyashita Y; Nakazato H; Nakao A; Sakamoto J
Jpn J Clin Oncol; 2005 Jun; 35(6):332-7. PubMed ID: 15961435
[TBL] [Abstract][Full Text] [Related]
39. Phase II study of sequential high-dose methotrexate and fluorouracil combined with doxorubicin as a neoadjuvant chemotherapy for scirrhous gastric cancer.
Takahashi S; Kinoshita T; Konishi M; Nakagouri T; Inoue K; Ono M; Sugitou M; Ohtsu A; Boku N; Yoshida S
Gastric Cancer; 2001; 4(4):192-7. PubMed ID: 11846062
[TBL] [Abstract][Full Text] [Related]
40. A phase II study of sequential methotrexate and 5-fluorouracil chemotherapy in previously treated gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group, JCOG 9207 trial.
Hamaguchi T; Shirao K; Yamamichi N; Hyodo I; Koizumi W; Seki S; Imamura T; Honma H; Ohtsu A; Boku N; Mukai T; Yamamoto S; Fukuda H; Yoshida S;
Jpn J Clin Oncol; 2008 Jun; 38(6):432-7. PubMed ID: 18515821
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
